These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35403284)
1. Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient. Omori R; Miyagaki T; Miyano K; Hashimoto Y; Kadono T J Dermatol; 2022 Aug; 49(8):e264-e265. PubMed ID: 35403284 [No Abstract] [Full Text] [Related]
2. Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. Ros J; Elez E Eur J Cancer; 2022 Sep; 172():326-328. PubMed ID: 35820242 [No Abstract] [Full Text] [Related]
12. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. Trullas A; Delgado J; Koenig J; Fuerstenau U; Dedorath J; Hausmann S; Stock T; Enzmann H; Pignatti F ESMO Open; 2021 Feb; 6(1):100031. PubMed ID: 33422765 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. Giuliani J; Mantoan B; Bonetti A J Oncol Pharm Pract; 2022 Jan; 28(1):199-202. PubMed ID: 34581610 [TBL] [Abstract][Full Text] [Related]
15. Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation. Ciccolini J; Milano G Ann Oncol; 2022 Sep; 33(9):981-982. PubMed ID: 35718337 [No Abstract] [Full Text] [Related]
16. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698 [TBL] [Abstract][Full Text] [Related]
19. Encorafenib, binimetinib and cetuximab combined therapy for patients with Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. Li S; Hu H; Ding D; Zhu Y; Huang J Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]